MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism
Globe Newswire•27/08/2026•08:00 ET
0
Whiz Insights
Get started
Create a free account to read the full story.